10x Genomics (TXG) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

10x Genomics

NasdaqGS•Healthcare•Health Information Services

$72.68-1.71(-0.02%)Pre-market

Market Cap

$10.00B

P/S

16.2x

P/B

12.1x

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

How this company scores

AverageMetricSide Score: 46/100

Strongest: Cash & Earnings Quality (16/25); weakest: Profitability (6/25).

Profitability6/25

Growth9/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality16/25

Strengths

Rising free cash flowInterest easily coveredProfit converts from growthNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 16.2x5y range 1.7x – 35.2x

Currently above its 20-quarter median.

P/B · 12.1x5y range 1.5x – 20.7x

Currently above its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

FCF consistently trails net income (avg -0.9x) — earnings may be inflated by non-cash items or aggressive accounting.

Price & Volume

Market Cap $10.00B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $616.91M
Q. Revenue: $151.04M
TTM EBITDA: $-48.40M
TTM Op. Income: $-88.38M
Q. Op. Income: $-19.55M
TTM Net Income: $-75.13M
Q. Net Income: $-17.93M
EPS: $-0.14
Shares Out.: $129.98M

$616.91M in TTM revenue declined 4.3% YoY, reaching $151.04M last quarter. TTM EBITDA of $-48.40M and TTM operating income of $-88.38M show growth is flowing through to the bottom line. However, net income is negative at $75.13M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has fallen for 2 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 74.5%
EBITDA Margin: -6.5%
Op. Margin: -12.9%
Net Margin: -11.9%

Op. margin of -12.9% is down 30.4% YoY — costs are rising relative to revenue. Net margin at -11.9% and gross margin of 74.5% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 174% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 16.2x
P/B Ratio: 12.1x

P/S of 16.2x and P/B of 12.1x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $1.03B
Cash: N/A
Long-Term Debt: N/A
Book Value: $825.55M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $16.97M
TTM Free Cash Flow: $121.44M
FCF Margin: 19.7%
FCF / Net Income: -1.6

TTM FCF of $121.44M on $16.97M in operating cash flow. The FCF / Net Income ratio of -1.6x means the business consumes cash — it is not yet self-funding. Across the last 8 quarters, free cash flow has fallen for 2 consecutive quarters — a weakening trend.